「lifeforpeoplearound the world」の検索結果
26件：21～25件目を表示
-
产品开发方针 | 研究与开发 | 千寿制药株式会社
发，从而为患者带去希望。 #1: 井上 佐智子, 川岛 素子, 坪田 一男：什么是干眼症？从原因到最新的治疗，Farumashia，2014 50(3): 201-6 #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...
http://www.senju.co.jp/chinese/rd/policy/ -
製品開発方針 | 研究開発活動 | 千寿製薬株式会社
開発に挑戦し続けています。 #1:井上 佐智子, 川島 素子, 坪田 一男：ドライアイとは？原因から最新の治療まで、ファルマシア, 2014 50(3): 201-6 #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...
https://www.senju.co.jp/rd/policy/ -
Product Development Policy | Research & Development | SENJU Pharmaceutica
Product Strategy DivisionExecutive OfficerYasunobu Maenaka With the management philosophy of “Good Company” and a company that shapes “Beyond eyesight,” Senju Pharmaceutical has developed products tha...
http://www.senju.co.jp/english/rd/policy/ -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Atsuhiro Kanda ARVO 2026 開催日：...
https://www.senju.co.jp/english/rd/society/ -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Atsuhiro Kanda ARVO 2026 開催日：...
http://www.senju.co.jp/english/rd/society/